Transplant/Artificial Liver
Liver Transplant/Artificial Liver
Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection
- Details
- Category: Liver Transplant/Artificial Liver
- Published on Wednesday, 20 February 2013 00:00
- Written by Novartis
The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).
Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Liz Highleyman
People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.
Researchers Grow Liver Tissue from Pluripotent Stem Cells
- Details
- Category: Liver Transplant/Artificial Liver
- Published on Friday, 22 June 2012 00:00
- Written by Liz Highleyman
Japanese researchers have produced liver-like tissue from induced pluripotent stem cells in the laboratory that can process drugs like a human liver, according to a presentation at the 10th annual meeting of the International Society for Stem Cell Research last week in Yokohama.
Entecavir (Baraclude) Label Adds Data on Black Patients and Liver Transplant Recipients with HBV
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 16 October 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration this week approved revised product information for entecavir (Baraclude) for the treatment of chronic hepatitis B virus (HBV) infection, adding new data from studies of African-American patients -- showing no differences in pharmacokinetics or safety -- and of people who received liver transplants. 
Changes Proposed for Allocation of Donated Livers
- Details
- Category: Liver Transplant/Artificial Liver
- Published on Thursday, 01 September 2011 00:00
- Written by Press Release
For some patients transplantation is the only treatment for advanced liver disease due to chronic hepatitis B, hepatitis C, liver cancer, alcoholism, or other causes. But the supply of donor livers does not meet the demand, meaning that many people die while on a waiting list. As described in the September 2011 issue of Liver Transplantation, experts have been meeting for the past 2 years to develop a modified allocation system that aims to reduce wait-list mortality.
Web Design and Development by